Structural Analysis and Optimization of NK1 Receptor Antagonists through Modulation of Atropisomer Interconversion Properties
- 23 December 2003
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (3) , 519-529
- https://doi.org/10.1021/jm030197g
Abstract
We have previously described a series of antagonists that showed high potency and selectivity for the NK(1) receptor. However, these compounds also had the undesirable property of existing as a mixture of interconverting rotational isomers. Here we show that alteration of the 2-naphthyl substituent can modulate the rate of isomer exchange. Comparisons of the NK(1) receptor affinity for the various conformational forms has facilitated the development of a detailed NK(1) pharmacophore model.Keywords
This publication has 29 references indexed in Scilit:
- Dual neurokinin NK1/NK2 receptor antagonistsDrugs of the Future, 1999
- Neurokinin Receptor AntagonistsCNS Drugs, 1997
- Conformational Analysis of Three NK1 Tripeptide Antagonists: A Proton Nuclear Magnetic Resonance StudyJournal of Medicinal Chemistry, 1997
- A Structural Rationale for the Design of Water Soluble Peptide-Derived Neurokinin-1 AntagonistsJournal of Receptors and Signal Transduction, 1997
- The primary structure and gene organization of human substance P and neuromedin K receptorsEuropean Journal of Biochemistry, 1992
- Molecular characterisation, expression and localisation of human neurokinin‐3 receptorFEBS Letters, 1992
- Human substance P receptor (NK-1): organization of the gene, chromosome localization and functional expression of cDNA clonesBiochemistry, 1991
- Molecular cloning, structural characterization and functional expression of the human substance P receptorBiochemical and Biophysical Research Communications, 1991
- Isolation and characterisation of the human lung NK-2 receptor gene using rapid amplification of cDNA endsBiochemical and Biophysical Research Communications, 1991
- A superactive antinociceptive pentapeptide, (D‐Met2,Pro5)‐enkephalinamideFEBS Letters, 1977